Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Pieter Sonneveld*, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broijl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Francesca Patriarca, Kalung Wu, Jolanda Droogendijk, Gerard Bos, Roman Hajek, Maria Teresa Petrucci, Paula Ypma, Nicholas Zojer, Monique C Minnema, Mario Boccadoro

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

INIS

Immunology and Microbiology